Gout – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of gout comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of gout for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s gout forecast will answer the following questions:
- In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of gout?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of gout over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases of gout for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following populations:
- Diagnosed prevalent cases of gout.
- Diagnosed incident cases of gout.
- Acute events of gout per year.
Note: Coverage may vary by country.
Table of contents
- Gout - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in / excluded from the analyses of gout)
- Diagnosed incident cases of gout
- Diagnosed prevalent cases of gout
- Diagnosed events of acute gout flares
- Drug-treated cases of acute gout flare events and prevalent cases of gout
- Risk / protective factors applied to disease forecast models
- Reference materials
